Open Access

β‑thalassemia caused by compound heterozygous mutations and cured by bone marrow transplantation: A case report

  • Authors:
    • Liusong Wu
    • Zhiyu Peng
    • Sen Lu
    • Mei Tan
    • Ying Rong
    • Runmei Tian
    • Yuhang Yang
    • Yan Chen
    • Jindong Chen
  • View Affiliations

  • Published online on: September 12, 2017     https://doi.org/10.3892/mmr.2017.7476
  • Pages: 6552-6557
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present study, a rare familial case of severe thalassemia with compound spontaneous mutations is reported. A 2.5‑year‑old boy, who suffered from severe anemia with yellowish skin, enlarged liver and spleen, was provided with a blood transfusion every 20 days to maintain hemoglobin levels between 90 and 100 g/l. Sanger sequencing combined with reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and Gap‑PCR revealed that the proband was a carrier of 4 compound heterozygous mutations: Hemoglobin subunit β (HBB):IVS‑II‑654(C>T)β+; Southeast Asian‑type‑hereditary persistence of fetal hemoglobin (SEA‑HPFH); HBB:c316‑148G>T; hemoglobin subunit α2 (HBA2):c.46G>A. The father of the proband was identified as a carrier of the heterozygous SEA‑HPFH mutation, the mother was a carrier of compound heterozygous mutations of HBB:IVS‑II‑654(C>T) and HBA2:c.46G>A, and the elder sister was heterozygous for HBB:IVS‑II‑654(C>T)β+. Based on these genetic results, it was determined that the proband had both of heavy β‑thalassemia and α‑thalassemia. Upon human leukocyte antigen matching, bone marrow transplantation (BMT) was successfully performed on the proband by selecting his HLA‑compatible sister as a donor. Following treatment, the proband was revealed to only carry the IVS‑II‑654(C>T)β+ heterozygous mutation, and further regular blood transfusions have been avoided; BMT results remained normal at six months follow‑up.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 16 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu L, Peng Z, Lu S, Tan M, Rong Y, Tian R, Yang Y, Chen Y and Chen J: β‑thalassemia caused by compound heterozygous mutations and cured by bone marrow transplantation: A case report. Mol Med Rep 16: 6552-6557, 2017.
APA
Wu, L., Peng, Z., Lu, S., Tan, M., Rong, Y., Tian, R. ... Chen, J. (2017). β‑thalassemia caused by compound heterozygous mutations and cured by bone marrow transplantation: A case report. Molecular Medicine Reports, 16, 6552-6557. https://doi.org/10.3892/mmr.2017.7476
MLA
Wu, L., Peng, Z., Lu, S., Tan, M., Rong, Y., Tian, R., Yang, Y., Chen, Y., Chen, J."β‑thalassemia caused by compound heterozygous mutations and cured by bone marrow transplantation: A case report". Molecular Medicine Reports 16.5 (2017): 6552-6557.
Chicago
Wu, L., Peng, Z., Lu, S., Tan, M., Rong, Y., Tian, R., Yang, Y., Chen, Y., Chen, J."β‑thalassemia caused by compound heterozygous mutations and cured by bone marrow transplantation: A case report". Molecular Medicine Reports 16, no. 5 (2017): 6552-6557. https://doi.org/10.3892/mmr.2017.7476